Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × HER2-positive Breast Cancer × tucatinib × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 7 Docetaxel 4 pertuzumab 3 Paclitaxel 3 tucatinib 1 pyrotinib 1 Injections 1 Carboplatin 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting

466 enrolled 17 charts

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡